Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.
Details on Person Signaling by EGFR is frequently activated in cancer through ...
| Class:Id | Summation:1181246 |
|---|---|
| _displayName | Signaling by EGFR is frequently activated in cancer through ... |
| _timestamp | 2014-11-13 16:09:27 |
| created | [InstanceEdit:1181247] Orlic-Milacic, Marija, 2011-02-02 |
| literatureReference | [LiteratureReference:1181035] Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [LiteratureReference:1181018] Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants [LiteratureReference:1181011] An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor [LiteratureReference:1169414] Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity [LiteratureReference:1181025] The juxtamembrane region of the EGF receptor functions as an activation domain [LiteratureReference:1217508] Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins [LiteratureReference:1221658] The Mechanism of Hsp90 regulation by the protein kinase-specific cochaperone p50(cdc37) [LiteratureReference:1225937] Targeting the oncogene and kinome chaperone CDC37 [LiteratureReference:1225923] Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors [LiteratureReference:1225925] Epidermal growth factor receptors with tyrosine kinase domain mutations exhibit reduced Cbl association, poor ubiquitylation, and down-regulation but are efficiently internalized [LiteratureReference:1181387] Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors [LiteratureReference:1225967] Novel mutant-selective EGFR kinase inhibitors against EGFR T790M [LiteratureReference:1248005] Interaction of Hsp90 with the nascent form of the mutant epidermal growth factor receptor EGFRvIII [LiteratureReference:1225829] Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways [LiteratureReference:1248643] Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma [LiteratureReference:1248637] Hypophosphorylation of residue Y1045 leads to defective downregulation of EGFRvIII [LiteratureReference:2008185] Glycosylation-induced conformational modification positively regulates receptor-receptor association: a study with an aberrant epidermal growth factor receptor (EGFRvIII/DeltaEGFR) expressed in cancer cells [LiteratureReference:2008165] Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain |
| modified | [InstanceEdit:1236384] Orlic-Milacic, Marija, 2011-03-25 [InstanceEdit:1247609] Orlic-Milacic, Marija, 2011-04-04 [InstanceEdit:1660590] Orlic-Milacic, Marija, 2011-10-13 [InstanceEdit:1660594] Orlic-Milacic, Marija, 2011-10-13 [InstanceEdit:1660595] Orlic-Milacic, Marija, 2011-10-13 [InstanceEdit:1834926] Orlic-Milacic, Marija, 2011-10-26 [InstanceEdit:2008182] Orlic-Milacic, Marija, 2011-11-21 [InstanceEdit:2008187] Orlic-Milacic, Marija, 2011-11-22 [InstanceEdit:2010556] Orlic-Milacic, Marija, 2011-11-22 [InstanceEdit:2010557] Orlic-Milacic, Marija, 2011-11-22 [InstanceEdit:2010559] Orlic-Milacic, Marija, 2011-11-22 [InstanceEdit:2010560] Orlic-Milacic, Marija, 2011-11-22 [InstanceEdit:2023014] Orlic-Milacic, Marija, 2011-12-01 [InstanceEdit:5637816] Orlic-Milacic, Marija, 2014-11-12 [InstanceEdit:5638311] Orlic-Milacic, Marija, 2014-11-13 |
| text | Signaling by EGFR is frequently activated in cancer through activating mutations in the coding sequence of the EGFR gene, resulting in expression of a constitutively active mutant protein. Epidermal growth factor receptor kinase domain mutants are present in ~16% of non-small-cell lung cancers (NSCLCs), but are also found in other cancer types, such as breast cancer, colorectal cancer, ovarian cancer and thyroid cancer. EGFR kinase domain mutants harbor activating mutations in exons 18-21 which code for the kinase domain (amino acids 712-979) . Small deletions, insertions or substitutions of amino acids within the kinase domain lock EGFR in its active conformation in which the enzyme can dimerize and undergo autophosphorylation spontaneously, without ligand binding (although ligand binding ability is preserved), and activate downstream signaling pathways that promote cell survival (Greulich et al. 2005, Zhang et al. 2006, Yun et al. 2007, Red Brewer et al. 2009). Point mutations in the extracellular domain of EGFR are frequently found in glioblastoma. Similar to kinase domain mutations, point mutations in the extracellular domain result in constitutively active EGFR proteins that signal in the absence of ligands, but ligand binding ability and responsiveness are preserved (Lee et al. 2006). EGFR kinase domain mutants need to maintain association with the chaperone heat shock protein 90 (HSP90) for proper functioning (Shimamura et al. 2005, Lavictoire et al. 2003). CDC37 is a co-chaperone of HSP90 that acts as a scaffold and regulator of interaction between HSP90 and its protein kinase clients. CDC37 is frequently over-expressed in cancers involving mutant kinases and acts as an oncogene (Roe et al. 2004, reviewed by Gray Jr. et al. 2008). Over-expression of the wild-type EGFR or EGFR cancer mutants results in aberrant activation of downstream signaling cascades, namely RAS/RAF/MAP kinase signaling and PI3K/AKT signaling, and possibly signaling by PLCG1, which leads to increased cell proliferation and survival, providing selective advantage to cancer cells that harbor activating mutations in the EGFR gene (Sordella et al. 2004, Huang et al. 2007). While growth factor activated wild-type EGFR is promptly down-regulated by internalization and degradation, cancer mutants of EGFR demonstrate prolonged activation (Lynch et al. 2004). Association of HSP90 with EGFR kinase domain mutants negatively affects CBL-mediated ubiquitination, possibly through decreasing the affinity of EGFR kinase domain mutants for phosphorylated CBL, so that CBL dissociates from the complex upon phosphorylation and cannot perform ubiquitination (Yang et al. 2006, Padron et al. 2007). Various molecular therapeutics are being developed to target aberrantly activated EGFR in cancer. Non-covalent (reversible) small tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, selectively bind kinase domain of EGFR, competitively inhibiting ATP binding and subsequent autophosphorylation of EGFR dimers. EGFR kinase domain mutants sensitive to non-covalent TKIs exhibit greater affinity for TKIs than ATP compared with the wild-type EGFR protein, and are therefore preferential targets of non-covalent TKI therapeutics (Yun et al. 2007). EGFR proteins that harbor point mutations in the extracellular domain also show sensitivity to non-covalent tyrosine kinase inhibitors (Lee et al. 2006). EGFR kinase domain mutants harboring small insertions in exon 20 or a secondary T790M mutation are resistant to reversible TKIs (Balak et al. 2006) due to increased affinity for ATP (Yun et al. 2008), and are targets of covalent (irreversible) TKIs that form a covalent bond with EGFR cysteine residue C397. However, effective concentrations of covalent TKIs also inhibit wild-type EGFR, causing severe side effects (Zhou et al. 2009). Hence, covalent TKIs have not shown much promise in clinical trials (Reviewed by Pao and Chmielecki in 2010). |
| (summation) | [Pathway:1169434] Signaling by constitutively active EGFR kinase domain mutants [Homo sapiens] [Pathway:1236382] Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants [Homo sapiens] |
| [Change default viewing format] | |
No pathways have been reviewed or authored by Signaling by EGFR is frequently activated in cancer through ... (1181246)
